Leading the Way in Life Science Technologies

GEN Exclusives

More »

Market and Technology Analysis

More »
Jan 30, 2014

Laboratory-Developed Tests Based on Mass Spec

In the realm of diagnostic tests, MS is making an impact.

Laboratory-Developed Tests Based on Mass Spec

A large number of LDTs based on mass spec are currently in the marketplace. [© Fotolia.com]

  • The focus of this GEN Market & Tech Analysis report is our continuing coverage of the mass spectrometry space as it's translating from research to clinic.

    Highlights of this report:

    • Mass spectrometry is making an impact in the clinic in the realm of diagnostic tests.
    • A number of laboratory-developed tests (LDTs) based on mass spectrometry have been developed and commercialized.
    • A wide swath of disease classes is addressed by these tests, which is encouraging as it suggests the deepening impact of mass spectrometry in the clinic arena.
    • We expect a growing number of bona fide diagnostics based on mass spectrometry going forward across a wide range of diseases/therapeutic indications.

    CLICK HERE to download the PDF report.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »